VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Source:http://linkedlifedata.com/resource/pubmed/id/18349829

Br. J. Cancer 2008 Apr 22 98 8 1366-79

Download in:

View as

Triples

General Info

PMID
18349829